Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Weekly vs 3-Weekly Cisplatin in Locally Advanced Nasopharyngeal Carcinoma
NCT01171781Phase 2Unknown
- Sponsor
- Samsung Medical Center
- Start
- Nov 2009
- Primary completion
- Jun 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of cisplatin in nasopharyngeal carcinoma (NPC) (2 arms), sponsored by Samsung Medical Center. Primary endpoint: Progression Free Survival Rate at 3 years. Status: unknown.
02
Drugs
cisplatin
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT01171781.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01171781.